Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Depreciation and Depletion (2022 - 2025)

Historic Depreciation and Depletion for Revolution Medicines (RVMD) over the last 4 years, with Q3 2025 value amounting to $2.0 million.

  • Revolution Medicines' Depreciation and Depletion rose 2500.0% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year increase of 1166.67%. This contributed to the annual value of $6.2 million for FY2024, which is 2400.0% up from last year.
  • As of Q3 2025, Revolution Medicines' Depreciation and Depletion stood at $2.0 million, which was up 2500.0% from $1.7 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Depreciation and Depletion ranged from a high of $2.0 million in Q3 2025 and a low of $900000.0 during Q1 2022
  • Moreover, its 4-year median value for Depreciation and Depletion was $1.3 million (2023), whereas its average is $1.4 million.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first surged by 3388.89% in 2023, then surged by 625.0% in 2025.
  • Over the past 4 years, Revolution Medicines' Depreciation and Depletion (Quarter) stood at $1.2 million in 2022, then grew by 10.45% to $1.3 million in 2023, then rose by 7.69% to $1.4 million in 2024, then soared by 42.86% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $1.7 million for Q2 2025, and $1.6 million during Q1 2025.